Pegademase Bovine (Adagen)

Adagen (pegademase bovine) is covered only for the FDA‑approved indication—treatment of adenosine deaminase (ADA) deficiency in severe combined immunodeficiency (SCID); off‑label uses are not covered. Coverage requires documentation of SCID due to ADA deficiency by enzyme assay or genetic testing, evidence the patient is not a candidate for or has failed bone marrow transplantation, that therapy will not be used to prepare/support transplantation, absence of severe thrombocytopenia, and authorization is limited to 12 months.

"Adagen® (pegademase bovine) is indicated for the treatment of adenosine deaminase deficiency in individuals having severe combined immunodeficiency disease."

Sign up to see full coverage criteria, indications, and limitations.